Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension

(1) Background: Arterial hypertension (HTN) is one of the most relevant cardiovascular risk factors. Nowadays multiple pharmaceutical treatment options exist with novel interventional methods (e.g., baroreflex activation therapy (BAT)) as a last resort to treat patients with resistant HTN. Although...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical medicine 2020-09, Vol.9 (9), p.3051
Hauptverfasser: Lipphardt, Mark, Dihazi, Hassan, Maas, Jens-Holger, Schäfer, Ann-Kathrin, Amlaz, Saskia I., Ratliff, Brian B., Koziolek, Michael J., Wallbach, Manuel
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 9
container_start_page 3051
container_title Journal of clinical medicine
container_volume 9
creator Lipphardt, Mark
Dihazi, Hassan
Maas, Jens-Holger
Schäfer, Ann-Kathrin
Amlaz, Saskia I.
Ratliff, Brian B.
Koziolek, Michael J.
Wallbach, Manuel
description (1) Background: Arterial hypertension (HTN) is one of the most relevant cardiovascular risk factors. Nowadays multiple pharmaceutical treatment options exist with novel interventional methods (e.g., baroreflex activation therapy (BAT)) as a last resort to treat patients with resistant HTN. Although pathophysiology behind resistant HTN is still not fully understood. There is evidence that selected biomarkers may be involved in the pathophysiology of HTN. (2) Methods: We investigated serum SDC4-levels in patients suffering from resistant HTN before and 6 months after BAT implantation. We collected 19 blood samples from patients with resistant HTN and blood pressure above target and measured serum SDC4-levels. (3) Results: Our results showed high serum SDC4-levels in patients with resistant HTN as compared to a healthy population. Patients with both, resistant HTN and diabetes mellitus type II, demonstrated higher serum SDC4-levels. β-blockers had lowering effects on serum SDC4-levels, whereas calcium channel blockers were associated with higher levels of serum SDC4. BAT implantation did not lead to a significant difference in serum SDC4-levels after 6 months of therapy. (4) Conclusion: Based on our results we propose SDC4 is elevated in patients suffering from resistant HTN. Thus, SDC4 might be a potential marker for endothelial dysfunction in patients with resistant hypertension.
doi_str_mv 10.3390/jcm9093051
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7564403</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2446661072</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-6eb4fd73350da20441abc40ef567793d31f5d73d6e95f4439000c32e03d6d4f33</originalsourceid><addsrcrecordid>eNpdkdFLHDEQxoNUVNQX_4KAL1JYO9lkN7cvglirBUVR-9CnkMtOvJx7yTXJWu6_b46TajsvM8z8-Pg-hpAjBqecd_BlbhYddBwatkX2apCyAj7hnz7Mu-QwpTmUmkxEzeQO2eV1J9mE8T3y83HlezTaV4LqRDW91fEFIw2WXvo-5BkOTg_06yrZ0ZvsgqfO03udHfqc6G-XZ_QBk0tZ-0yvV0uMGX0q3AHZtnpIePjW98mPb5dPF9fVzd3V94vzm8oUb7lqcSpsLzlvoNc1CMH01AhA27RSdrznzDbl3LfYNVaIEhnA8BqhrHphOd8nZxvd5ThdYG-Kr6gHtYxuoeNKBe3UvxfvZuo5vCrZtELAWuDkTSCGXyOmrBYuGRwG7TGMSdVCtG3LQNYFPf4PnYcx-hJP1a1grIGiV6jPG8rEkFJE-9cMA7V-mnp_Gv8D_CeIEg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2641150033</pqid></control><display><type>article</type><title>Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Lipphardt, Mark ; Dihazi, Hassan ; Maas, Jens-Holger ; Schäfer, Ann-Kathrin ; Amlaz, Saskia I. ; Ratliff, Brian B. ; Koziolek, Michael J. ; Wallbach, Manuel</creator><creatorcontrib>Lipphardt, Mark ; Dihazi, Hassan ; Maas, Jens-Holger ; Schäfer, Ann-Kathrin ; Amlaz, Saskia I. ; Ratliff, Brian B. ; Koziolek, Michael J. ; Wallbach, Manuel</creatorcontrib><description>(1) Background: Arterial hypertension (HTN) is one of the most relevant cardiovascular risk factors. Nowadays multiple pharmaceutical treatment options exist with novel interventional methods (e.g., baroreflex activation therapy (BAT)) as a last resort to treat patients with resistant HTN. Although pathophysiology behind resistant HTN is still not fully understood. There is evidence that selected biomarkers may be involved in the pathophysiology of HTN. (2) Methods: We investigated serum SDC4-levels in patients suffering from resistant HTN before and 6 months after BAT implantation. We collected 19 blood samples from patients with resistant HTN and blood pressure above target and measured serum SDC4-levels. (3) Results: Our results showed high serum SDC4-levels in patients with resistant HTN as compared to a healthy population. Patients with both, resistant HTN and diabetes mellitus type II, demonstrated higher serum SDC4-levels. β-blockers had lowering effects on serum SDC4-levels, whereas calcium channel blockers were associated with higher levels of serum SDC4. BAT implantation did not lead to a significant difference in serum SDC4-levels after 6 months of therapy. (4) Conclusion: Based on our results we propose SDC4 is elevated in patients suffering from resistant HTN. Thus, SDC4 might be a potential marker for endothelial dysfunction in patients with resistant hypertension.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm9093051</identifier><identifier>PMID: 32971813</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Angiogenesis ; Antihypertensives ; Atherosclerosis ; Blood pressure ; Body mass index ; Cardiology ; Clinical medicine ; Endothelium ; Enzymes ; Heart attacks ; Hypertension ; Kidney diseases ; Kinases ; Patients ; Software ; Variance analysis</subject><ispartof>Journal of clinical medicine, 2020-09, Vol.9 (9), p.3051</ispartof><rights>2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-6eb4fd73350da20441abc40ef567793d31f5d73d6e95f4439000c32e03d6d4f33</citedby><cites>FETCH-LOGICAL-c383t-6eb4fd73350da20441abc40ef567793d31f5d73d6e95f4439000c32e03d6d4f33</cites><orcidid>0000-0002-1162-4682</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564403/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564403/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Lipphardt, Mark</creatorcontrib><creatorcontrib>Dihazi, Hassan</creatorcontrib><creatorcontrib>Maas, Jens-Holger</creatorcontrib><creatorcontrib>Schäfer, Ann-Kathrin</creatorcontrib><creatorcontrib>Amlaz, Saskia I.</creatorcontrib><creatorcontrib>Ratliff, Brian B.</creatorcontrib><creatorcontrib>Koziolek, Michael J.</creatorcontrib><creatorcontrib>Wallbach, Manuel</creatorcontrib><title>Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension</title><title>Journal of clinical medicine</title><description>(1) Background: Arterial hypertension (HTN) is one of the most relevant cardiovascular risk factors. Nowadays multiple pharmaceutical treatment options exist with novel interventional methods (e.g., baroreflex activation therapy (BAT)) as a last resort to treat patients with resistant HTN. Although pathophysiology behind resistant HTN is still not fully understood. There is evidence that selected biomarkers may be involved in the pathophysiology of HTN. (2) Methods: We investigated serum SDC4-levels in patients suffering from resistant HTN before and 6 months after BAT implantation. We collected 19 blood samples from patients with resistant HTN and blood pressure above target and measured serum SDC4-levels. (3) Results: Our results showed high serum SDC4-levels in patients with resistant HTN as compared to a healthy population. Patients with both, resistant HTN and diabetes mellitus type II, demonstrated higher serum SDC4-levels. β-blockers had lowering effects on serum SDC4-levels, whereas calcium channel blockers were associated with higher levels of serum SDC4. BAT implantation did not lead to a significant difference in serum SDC4-levels after 6 months of therapy. (4) Conclusion: Based on our results we propose SDC4 is elevated in patients suffering from resistant HTN. Thus, SDC4 might be a potential marker for endothelial dysfunction in patients with resistant hypertension.</description><subject>Angiogenesis</subject><subject>Antihypertensives</subject><subject>Atherosclerosis</subject><subject>Blood pressure</subject><subject>Body mass index</subject><subject>Cardiology</subject><subject>Clinical medicine</subject><subject>Endothelium</subject><subject>Enzymes</subject><subject>Heart attacks</subject><subject>Hypertension</subject><subject>Kidney diseases</subject><subject>Kinases</subject><subject>Patients</subject><subject>Software</subject><subject>Variance analysis</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkdFLHDEQxoNUVNQX_4KAL1JYO9lkN7cvglirBUVR-9CnkMtOvJx7yTXJWu6_b46TajsvM8z8-Pg-hpAjBqecd_BlbhYddBwatkX2apCyAj7hnz7Mu-QwpTmUmkxEzeQO2eV1J9mE8T3y83HlezTaV4LqRDW91fEFIw2WXvo-5BkOTg_06yrZ0ZvsgqfO03udHfqc6G-XZ_QBk0tZ-0yvV0uMGX0q3AHZtnpIePjW98mPb5dPF9fVzd3V94vzm8oUb7lqcSpsLzlvoNc1CMH01AhA27RSdrznzDbl3LfYNVaIEhnA8BqhrHphOd8nZxvd5ThdYG-Kr6gHtYxuoeNKBe3UvxfvZuo5vCrZtELAWuDkTSCGXyOmrBYuGRwG7TGMSdVCtG3LQNYFPf4PnYcx-hJP1a1grIGiV6jPG8rEkFJE-9cMA7V-mnp_Gv8D_CeIEg</recordid><startdate>20200922</startdate><enddate>20200922</enddate><creator>Lipphardt, Mark</creator><creator>Dihazi, Hassan</creator><creator>Maas, Jens-Holger</creator><creator>Schäfer, Ann-Kathrin</creator><creator>Amlaz, Saskia I.</creator><creator>Ratliff, Brian B.</creator><creator>Koziolek, Michael J.</creator><creator>Wallbach, Manuel</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1162-4682</orcidid></search><sort><creationdate>20200922</creationdate><title>Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension</title><author>Lipphardt, Mark ; Dihazi, Hassan ; Maas, Jens-Holger ; Schäfer, Ann-Kathrin ; Amlaz, Saskia I. ; Ratliff, Brian B. ; Koziolek, Michael J. ; Wallbach, Manuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-6eb4fd73350da20441abc40ef567793d31f5d73d6e95f4439000c32e03d6d4f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Angiogenesis</topic><topic>Antihypertensives</topic><topic>Atherosclerosis</topic><topic>Blood pressure</topic><topic>Body mass index</topic><topic>Cardiology</topic><topic>Clinical medicine</topic><topic>Endothelium</topic><topic>Enzymes</topic><topic>Heart attacks</topic><topic>Hypertension</topic><topic>Kidney diseases</topic><topic>Kinases</topic><topic>Patients</topic><topic>Software</topic><topic>Variance analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lipphardt, Mark</creatorcontrib><creatorcontrib>Dihazi, Hassan</creatorcontrib><creatorcontrib>Maas, Jens-Holger</creatorcontrib><creatorcontrib>Schäfer, Ann-Kathrin</creatorcontrib><creatorcontrib>Amlaz, Saskia I.</creatorcontrib><creatorcontrib>Ratliff, Brian B.</creatorcontrib><creatorcontrib>Koziolek, Michael J.</creatorcontrib><creatorcontrib>Wallbach, Manuel</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lipphardt, Mark</au><au>Dihazi, Hassan</au><au>Maas, Jens-Holger</au><au>Schäfer, Ann-Kathrin</au><au>Amlaz, Saskia I.</au><au>Ratliff, Brian B.</au><au>Koziolek, Michael J.</au><au>Wallbach, Manuel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension</atitle><jtitle>Journal of clinical medicine</jtitle><date>2020-09-22</date><risdate>2020</risdate><volume>9</volume><issue>9</issue><spage>3051</spage><pages>3051-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>(1) Background: Arterial hypertension (HTN) is one of the most relevant cardiovascular risk factors. Nowadays multiple pharmaceutical treatment options exist with novel interventional methods (e.g., baroreflex activation therapy (BAT)) as a last resort to treat patients with resistant HTN. Although pathophysiology behind resistant HTN is still not fully understood. There is evidence that selected biomarkers may be involved in the pathophysiology of HTN. (2) Methods: We investigated serum SDC4-levels in patients suffering from resistant HTN before and 6 months after BAT implantation. We collected 19 blood samples from patients with resistant HTN and blood pressure above target and measured serum SDC4-levels. (3) Results: Our results showed high serum SDC4-levels in patients with resistant HTN as compared to a healthy population. Patients with both, resistant HTN and diabetes mellitus type II, demonstrated higher serum SDC4-levels. β-blockers had lowering effects on serum SDC4-levels, whereas calcium channel blockers were associated with higher levels of serum SDC4. BAT implantation did not lead to a significant difference in serum SDC4-levels after 6 months of therapy. (4) Conclusion: Based on our results we propose SDC4 is elevated in patients suffering from resistant HTN. Thus, SDC4 might be a potential marker for endothelial dysfunction in patients with resistant hypertension.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>32971813</pmid><doi>10.3390/jcm9093051</doi><orcidid>https://orcid.org/0000-0002-1162-4682</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2077-0383
ispartof Journal of clinical medicine, 2020-09, Vol.9 (9), p.3051
issn 2077-0383
2077-0383
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7564403
source PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Angiogenesis
Antihypertensives
Atherosclerosis
Blood pressure
Body mass index
Cardiology
Clinical medicine
Endothelium
Enzymes
Heart attacks
Hypertension
Kidney diseases
Kinases
Patients
Software
Variance analysis
title Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A09%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Syndecan-4%20as%20a%20Marker%20of%20Endothelial%20Dysfunction%20in%20Patients%20with%20Resistant%20Hypertension&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Lipphardt,%20Mark&rft.date=2020-09-22&rft.volume=9&rft.issue=9&rft.spage=3051&rft.pages=3051-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm9093051&rft_dat=%3Cproquest_pubme%3E2446661072%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2641150033&rft_id=info:pmid/32971813&rfr_iscdi=true